ACTAS DERMO-SIFILIOGRAFICAS Journal

Overview
Identity
Ver todos

publication venue for

52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience 2024
Clinical-epidemiological profile, and treatment response in relation to associated atopic comorbidity in atopic dermatitis. Experience from the BIOBADATOP Registry.¿ ¿Perfil clínico, epidemiológico y respuesta al tratamiento, en función de la comorbilidad atópica asociada en la dermatitis atópica. Experiencia del registro BIOBADATOP. 1-10. 2024
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). Supervivencia de la ciclosporina en el tratamiento de la dermatitis atópica moderada-grave: Registro Español de Dermatitis Atópica (BIOBADATOP). . 341-346. 2024
Eficacia a medio plazo (52 semanas) de tildrakizumab en el tratamiento de la psoriasis moderada a severa: un estudio multicéntrico de práctica clínica. 722-725. 2024
Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial.; Mantenimiento a 4 anos del aclaramiento completo con bimekizumab en 10 pacientes en Espana procedentes del estudio BE RADIANT 2024
MID-TERM SAFETY AND EFFICACY OF UPADACITINIB IN ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A REAL-LIFE 34-PATIENT MULTICENTER TRIAL. 1-2. 2024
Mantenimiento a 4 años del aclaramiento completo con bimekizumab en 10 pacientes en Espa¿na procedentes del estudio BE RADIANT 2024
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study 2024
Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients. 654-662. 2024
Valoración de la medida de Actividad Mínima deEnfermedad en Psoriasis en Espa¿na: estudiotransversal nacionalG 2024
BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings. 479-487. 2023
Common Approach to Metabolic-Associated Fatty Liver Disease in Patients With Psoriasis: Consensus-Based Recommendations From a Multidisciplinary Group of Experts. 392-401. 2023
Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). 2023
Moderate to Severe Psoriasis in Older Adults: Recommendations on Management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). 2023
Recomendaciones del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología sobre el manejo del paciente de edad avanzada con psoriasis en placas moderada-grave. 2023
Implementation of Recommendations for the Management of Psoriasis During, Pregnancy, Postpartum, Breastfeeding, and Perinatal Care. 666-673. 2022
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. 401-406. 2022
Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Therapy. 262-277. 2022
Precision Medicine in Psoriasis. 755-757. 2022
Psoriasis ungueal. 481-490. 2022
Board of Directors of the AEDV. Strategic Plan for the Spanish Academy of Dermatology and Venerology (AEDV): FuturAEDV 2013-2017. 639-654. 2014
Comparative Epidemiologic Study of Skin Diseases in Foreign Children and Children of Spanish Origin in Alicante, Spain. 394-400. 2014
Estudio multicéntrico de casos y controles sobre factores de riesgo de desarrollar un melanoma cutáneo en la Comunidad Valenciana. 790-797. 2012
Polypodium leucotomos extract in atopic dermatitis: a randomized, double-blind, placebo-controlled, multicenter trial.. 599-607. 2012